

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Man *et al.*

Confirmation No.: 7683

Application No.: 10/685,942

Group Art Unit: 1611

Filed: October 14, 2003

Examiner: Frazier, B.

For: PHARMACEUTICALLY ACTIVE
ISOINDOLINE DERIVATIVES

Atty Docket No.: 9516-205-999
(JD 501872-999204)

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Celgene Corporation is the assignee of the entire right, title and interest in and to U.S. Patent Application No. 12/368,245 ("the '245 application") by virtue of an assignment from George W. Muller and Hon-Wah Man to Celgene Corporation executed in connection with U.S. Application No. 10/900,270 (a parent of the '245 application) and recorded at Reel 016018, Frame 0203.

Celgene Corporation is also the assignee of the entire right, title and interest in and to the above-identified application by virtue of an assignment from Hon-Wah Man and George W. Muller to Celgene Corporation, which was recorded at Reel 025903, Frame 0619.

Celgene Corporation hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the '245 application, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that the patent shall be commonly owned with the '245 application.


Petitioner does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration of the full statutory term of '245 application in the event that the '245 application later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in

whole or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full statutory term, except for the separation of the common ownership stated above. This disclaimer is to be binding upon the grantee, its successors, or assigns.

A fee of \$ 140.00 is believed due under 37 C.F.R. 120(d) for the submission of this terminal disclaimer. Please charge this, and any other required fees, to Jones Day Deposit Account No. 503013. A copy of this sheet is enclosed.

Respectfully submitted,

Date March 7, 2011

Signed: 
By: Robert J. Hughes
Title: Chief Executive Officer